NASDAQ:BDTX

Black Diamond Therapeutics Stock News

etoro logo Buy BDTX
*Your capital is at risk
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of sm
CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
CAMBRIDGE, Mass. and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today
•Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 insertion mutation  �
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Black Diamond Therapeutics (NASDAQ:REYN) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday, ValuEngine reports. A number
CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
Noble Midstream Partners LP (NASDAQ: NBLX) (“Noble Midstream” or the “Partnership”) today reported second-quarter 2020 financial and operational resul
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
CAMBRIDGE, Mass. and NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal
Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE